Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lexaria Bioscience Corp (NQ: LEXX ) 3.200 +0.110 (+3.56%) Streaming Delayed Price Updated: 12:22 PM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Lexaria Bioscience Corp < Previous 1 2 ... 9 10 11 12 13 14 15 16 17 ... 22 23 Next > CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Hypertension Drug Market with Proprietary Drug-Delivery Method September 20, 2022 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Hypertension Drug Market with Proprietary Drug-Delivery Method September 20, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience: Taking Aim at the $28 Billion Hypertension Market; Human Clinical Study Yields Remarkable Results September 20, 2022 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Exposures Product Safety Lexaria Discusses Valuation Metrics for Biotech Industry August 11, 2022 Via ACCESSWIRE Lexaria Bioscience Corp. (NASDAQ: LEXX), Growing its Market Share, One Patent at a Time September 16, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Hypertension Treatment Program Stands Distinct September 15, 2022 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Product Safety CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Hypertension Treatment Program Stands Distinct September 15, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Product Safety Lexaria Bioscience Corp. (NASDAQ: LEXX) Strengthens Board of Directors to Boost Efforts toward Regulatory Approval of Potential Treatment for Hypertension September 14, 2022 Via Investor Brand Network Lexaria Bioscience Corp. (NASDAQ: LEXX) Acquires 27th Worldwide Patent Applying to a Range of APIs in Ready-to-Drink Consumer Retail Beverage Products September 12, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Quest to Find Hypertension Treatment Promising With DehydraTECH(TM)’s Ability to Boost Bioavailability September 06, 2022 Via Investor Brand Network CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints New Board Member September 02, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Product Safety CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints New Board Member September 02, 2022 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Product Safety Lexaria Welcomes Dr. Catherine Turkel to its Board of Directors September 02, 2022 Via ACCESSWIRE TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces New Patent in Mexico August 31, 2022 Via Investor Brand Network Topics Cannabis Intellectual Property Exposures Cannabis Intellectual Property Lexaria Receives New Patent in Mexico August 31, 2022 Via ACCESSWIRE Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces the Availability of a Broadcast titled, “The Power of Science to Stop a Killer” August 30, 2022 Via Investor Brand Network Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Drug Development Program and Recent FDA Confirmation Position It for Favorable Valuation August 26, 2022 Via Investor Brand Network Exposures Product Safety CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands to Gain Substantial Revenue Through Licensing of DehydraTECH(TM) August 22, 2022 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands to Gain Substantial Revenue Through Licensing of DehydraTECH(TM) August 22, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Delighted About Well-Received DehydraTECH-CBD Proposals by the FDA; Maintains Late 2022/Early 2023 Target For Complete IND Application August 19, 2022 Via Investor Brand Network TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH Capable of Delivering APIs More Efficiently by Overcoming Food Effect August 17, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Four Partnerships, Boosts ‘Revenue Picture’ August 16, 2022 Via Investor Brand Network Lexaria Bioscience Corp. (NASDAQ: LEXX) Inches Closer to DehydraTECH-CBD FDA Evaluation Following Successful Dosing in Multi-Week HYPER-H21-4 Human Clinical Study August 12, 2022 Via Investor Brand Network Exposures Product Safety NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pioneering Innovative Hypertension Treatments August 11, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Discusses Biotech Industry Valuation Metrics August 11, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Positive FDA Feedback Concerning Opening IND Program August 10, 2022 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Product Safety CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Positive FDA Feedback Concerning Opening IND Program August 10, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Product Safety New Drugs in Pipeline for Hypertension, the Silent Global Pandemic August 10, 2022 Via Investor Brand Network Exposures Product Safety New Drugs in Pipeline for Hypertension, the Silent Global Pandemic August 10, 2022 NetworkNewsWire Editorial Coverage New York, NY – August 10, 2022 – In medicine, there is a term called “clinical inertia,” or the case of what someone doesn’t know — or what they ignore — could kill... Via FinancialNewsMedia Exposures Product Safety Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension August 10, 2022 Via ACCESSWIRE < Previous 1 2 ... 9 10 11 12 13 14 15 16 17 ... 22 23 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.